Your session is about to expire
← Back to Search
Merestinib for Non-Small Cell Lung Cancer
Study Summary
This trial is testing merestinib as a possible treatment for NSCLC with a specific MET gene change or for solid tumors with an NTRK gene alteration.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have taken NTRK inhibitors before but am not on blood thinners, or it's deemed safe to pause them for a biopsy.Your kidney function, measured by a blood test called serum creatinine, should be within a certain range.My high blood pressure is not controlled, even with medication.I don't have major stomach or bowel issues affecting medication absorption.You have had allergic reactions to drugs similar to merestinib.Your liver enzymes (AST and ALT) should be within a certain range, unless you have cancer that has spread to the liver, in which case a higher level is acceptable.I haven't had chemotherapy, immune therapy, major surgery, or radiotherapy in the last 3 weeks.I do not have HIV.I do not have untreated brain metastases and any previous ones have been stable for over 4 weeks.I have not taken any TKI medication for a period long enough since my last dose.Your platelet count is at least 100,000 per microliter.I have a tumor that can be measured with scans or exams.I am 18 years old or older.I do not have any serious illnesses that would stop me from following the study's requirements.I am not pregnant or breastfeeding.My cancer has an NTRK gene change confirmed by a specific test.I agree to use birth control during and up to 4 months after the study.Your white blood cell count is at least 1.5 thousand per microliter.Your hemoglobin level is at least 9 grams per deciliter, with or without needing a blood transfusion.I have had NTRK inhibitor treatment and agree to a tumor biopsy.My organ and bone marrow functions are normal.I can swallow pills or have a feeding tube for medication.I can carry out all my self-care activities without help.I am 18 years old or older.I have an advanced solid tumor and have been treated for it before.I can carry out all my self-care but cannot do heavy physical work.I had another type of cancer but it was treated successfully and hasn’t come back in over 3 years.I have advanced NSCLC and have undergone at least one treatment for it.I have taken a MET inhibitor before and am not on blood thinners, or it's safe to pause them for a biopsy.My cancer has a MET exon 14 mutation confirmed by a specific genetic test.I have had MET inhibitor treatment and agree to a tumor biopsy.Your bilirubin levels are within a certain range based on the normal levels at the hospital.
- Group 1: NSCLC (Met Exon 14 Mutation)
- Group 2: Solid Tumor (NTRK1,2,3 Rearrangement)
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are there any available openings for people who want to participate in this research?
"This study, which was published on clinicaltrials.gov on November 11th 2016 and last updated on August 22nd 2022, is no longer recruiting patients. There are 2410 other trials that are currently open for enrollment."
Could you please detail the risks associated with Merestinib?
"Merestinib's safety is estimated to be a 2. This is because, while there is data suggesting that it is safe, there is no evidence yet of its efficacy."
If so, could you please detail the findings of prior Merestinib clinical trials?
"At this time, there are 3 ongoing clinical trials assessing Merestinib's efficacy and 0 of these studies have reached Phase 3. The majority of the research is being conducted in San Antonio, Texas; however, there are a total of 104 locations running Merestinib clinical trials."
Does this research represent a new frontier for treatments?
"Research into merestinib started in 2016 with a clinical trial conducted by Eli Lilly and Company. After the initial study involving 309 people, merestinib received Phase 2 drug approval in [year]. As of now, there are 3 active studies being done for Merestinib across 18 cities and 20 countries."
Who else is applying?
How old are they?
What portion of applicants met pre-screening criteria?
Share this study with friends
Copy Link
Messenger